CD96, among T cell genes, is considered a novel immune checkpoint receptor target [155], and higher expression was associated with a poorer clinical outcome [156], while low LCK expression has been identified as a potential prognostic biomarker for immunotherapy in HCC [157]; however, the study did not segregate patients based on viral infection. This evidence concerns the gene CD96 and hepatocellular carcinoma.